Kornimate/medical-research-clean huggingface dataset:
feasibility of monitoring patients during radiotherapy using biometric sensor data: the oncowatch study 1.0

Conditions: Head and Neck Cancer

Summary: the aim of the study is to determine the adherence to using an apple watch during curative intended radiotherapy for head and neck cancer. secondly it will bring new insights to the patient's activity levels and how heart rate varies during treatment course.

patients with head and neck cancer (hnc) experience severe side effects during radiotherapy (rt). ongoing technological advances in wearable biometric sensors allow for real-time collection of objective data e.g. physical activity and heart rate, which in the future might help to detect and act against side effects before they become severe. a smartwatch such as the apple watch allows for objective data monitoring outside hospital with minimal effort for the patient. to find out if such tools can be implemented in the oncological setting feasibility studies are needed. the aim of the study is to determine the adherence to using an apple watch during curative intended radiotherapy for head and neck cancer. secondly it will bring new insights to the patient's activity levels and how heart rate varies during treatment course. the study will assess the feasibility of using the apple watch for home monitoring of patients with hnc. it will bring new insights to the patient's activity levels and how heart rate varies during treatment course. this is important knowledge before further investigating how biometric data can be used as part of symptom monitoring.

Eligibility criteria:
inclusion criteria: * danish patients ≥18 years planned to primary or post-operative curative radiotherapy for squamous-cell carcinoma of the head and neck at rigshospitalet, university hospital, department of oncology, denmark. * able to read and speak danish exclusion criteria: * seious cognitive deficits

Keywords: smartwatch radiotherapy
weekly docetaxel and bortezomib in the treatment of advanced hormone-refractory prostate cancer

Conditions: Prostate Cancer

Summary: evaluation of the effectiveness of weekly docetaxel/bortezomib as first-line chemotherapy for patients with advanced hormone-refractory prostate cancer.

upon determination of eligibility, patients will be receive: * docetaxel + bortezomib patients with objective responses or stable disease will continue treatment for eight courses or until disease progression is documented.

Eligibility criteria:
inclusion criteria: * prostate cancer, and objective evidence of metastatic disease * progression while receiving androgen ablation therapy * no previous chemotherapy * measurable or evaluable disease in conjunction with elevated serum psa levels * ecog performance status 0, 1, or 2 * adequate bone marrow, liver and kidney function * voluntarily provide written informed consent exclusion criteria: you cannot participate in this study if any of the following apply to you: * moderate or severe peripheral neuropathy * age \< 18 years * other serious medical conditions that may interfere with protocol therapy * other active malignancies * history of treatment for other invasive cancers within 3 years please note: there are additional inclusion/exclusion criteria. the study center will determine if you meet all of the criteria. if you do not qualify for the trial, study personnel will explain the reasons. if you do qualify, study personnel will explain the trial in detail and answer any questions you may have.
broxuridine plus surgery in treating patients with stage i or stage ii prostate cancer

Conditions: Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer

Summary: phase ii trial to study the effectiveness of broxuridine in treating patients who are undergoing surgery for stage i or stage ii prostate cancer. broxuridine may help doctors determine the rate of growth of prostate tumors and help them plan effective treatment

objectives: i. measure the potential doubling times of multifocal adenocarcinomas of the prostate using broxuridine. ii. determine whether the doubling times of multifocal carcinomas occurring within a single prostate are consistent with a model in which low-volume carcinomas have slow doubling times and high-volume carcinomas have fast doubling times. outline: patients receive broxuridine iv over 30 minutes on day -1. approximately 12-96 hours later, patients undergo surgery to remove the prostate. tumor tissue is examined by immunostaining for the presence of broxuridine to determine doubling times of the tumor.

Eligibility criteria:
inclusion criteria: * diagnosis of stage i or ii (t1-2) carcinoma of the prostate * psa greater than 8 ng/ml * abnormal findings on digital rectal examination * eligible for radical prostatectomy * performance status - ecog 0 or 1 * no prior biologic therapy * no prior chemotherapy * no prior neoadjuvant hormonal therapy * no prior radiotherapy * see disease characteristics * no prior therapy that would affect tumor growth rates or volume
interactive power toothbrush with or without app vs manual toothbrush

Conditions: Toothbrushes

Summary: it has been suggested that interactive power toothbrushes (ptbs), developed in recent years, provide more successful results in plaque control and effective use of brushing time by enabling patient collaboration and self-treatment, thanks to the application features associated with mobile phones. interactive ptb synchronized with smartphones, including real-time feedback, session length, applications that prevent excessive brushing force, and focus brushing on specific areas with position detection technology, increases the brushing performance by increasing oral hygiene motivation. studies report that both power and manual toothbrushes cause gingival abrasion, a localized reversible lesion of the epithelium. while the opinions about the cause of gingival abrasion are not clear yet, the discussions regarding brush strength yet continue. while it is possible to control the interactive ptb force thanks to the mobile application, it is known that these high-speed rotating brushes control plaque effectively, but there is not enough evidence about its effect on gingival abrasion. the primary purpose of this clinical study is to determine whether interactive ptb with application feature provides an additional benefit on plaque removal efficacy and reduction of gingival inflammation. in addition, this study aims to determine the effect of interactive power toothbrush with application on gingival abrasion by comparing it to interactive ptb without application and manual toothbrush. the study's null hypothesis in terms of gingival abrasion is that interactive ptb do not show a significant difference from other brushing methods.


Eligibility criteria:
inclusion criteria: * dental students * diagnosed with gingivitis * clinical measurements: probing pocket depths ≤3 mm, qhpi-tm ≥ 1.75 and with a bleeding site of at least 40% or more * aged between 18-25 * non-smoker * no systemic diseases * not undergoing orthodontic treatment * no crowding * no periodontal treatment in the last three months exclusion criteria: * use of power toothbrush before * use of drugs that may affect the gingival tissues * having mucogingival problems * having carious teeth that require urgent treatment * probing pocket depths ˃ 3mm
the influence of amh on ovarian responsiveness to ovulation induction with gnrh in women with pcos

Conditions: Infertility

Summary: the investigator suggests that pcos women with high amh levels are resistant to ovarian stimulation and may need adjustment of the dose of gonadotrophin.

there is a correlation between high levels of amh and the severity of pcos. excessive amh may have a negative effect on the sensitivity of the resting follicles to gonadotropins. this is an observational prospective study to investigate the impact of circulating amh on gonadotrophin induction in women with pcos.

Eligibility criteria:
inclusion criteria: * women of age 18 - 35 years * bmi 20 - 30 kg/m2 * anovulatory infertility * diagnosis of pcos based on rotterdam consensus criteria (two of three criteria: oligo/anovulation, hyperandrogenaemia and sonographic appearance of polycystic ovaries) exclusion criteria: * women above 35 years or under 18 years * women with bmi above 30 kg/m2 or under 20 kg/m2 * normally ovulating women * patients with marked hyperandrogenaemia were screened for congenital adrenal hyperplasia (by measuring serum concentration of 17alpha hydroxyl-progesterone) or patients with cushing syndrome (by measuring urinary free cortisol)

Keywords: anti-müllerian hormone ovarian stimulation polycystic ovary syndrome intracytoplasmic sperm injection
red light intervention on myopic progression

Conditions: Myopia

Summary: to explore the effectiveness of using repeated low-level red-light therapy to slow myopia progression.


Eligibility criteria:
inclusion criteria: 1. age at enrolment: 6-12 years; 2. at least one eye with spherical equivalent refractions (sers): -1.00 to -5.00 diopters (d), and stigmatism of 1.50 d or less; 3. anisometropia of 1.5 d or less; 4. the bcva of distant vision is at least 0.8; 5. myopia progressed more than 0.5d in the past year; 6. have normal thinking and language communication skills, and be able to actively cooperate with the treatment as required; 7. written informed consent of guardian and child. exclusion criteria: 1. strabismus, amblyopia or other ocular abnormalities; 2. other systemic abnormalities; 3. prior treatment of myopia control in 6 months, e.g. drugs, orthokeratology, progressive addition lenses, bifocal lenses, etc in either eye; 4. atropine allergy; 5. other situations that not suitable for participating in the trial as judged by the researcher.
the optimization of iron bioavailability of supplements using hepcidin levels in humans

Conditions: Iron Deficiency

Summary: background: oral iron supplementation (ois) is a widely-used strategy to treat iron deficiency anemia. however, absorption of ois is often low and response is variable. to overcome this, large doses are given but this may reduce compliance due to gastric irritation. thus, ois doses should be low, while maximizing absorption. the prevailing serum hepcidin concentration (shep) is the major determinant of iron absorption and erythrocyte iron utilization. based on limited data in humans, shep can be increased by a single ois dose but the duration of the increase is uncertain: in a recent study conducted in our laboratory it has been found to last approx. 24 h. also, there are few data on how the increase in shep determines the absorption of further doses of oral iron. is there a threshold shep at which subsequent iron absorption is sharply reduced? better understanding of this relationship would be valuable to design more effective and safer ois regimens. objectives: 1) determine whether two consecutive dosages of 60 mg fe differently affect hepcidin response and iron bioavailability (study 1) 2) compare the bioavailability of iron supplement dosages given at different times of the day (study 2). methods/subjects: healthy female subjects will be screened for low iron status. anemic subjects will be excluded from the study. thirty two subjects will be included with serum ferritin \ 117 g/l. subjects will be randomized in two groups and their hepcidin (shep) and iron status markers monitored at day 1 (baseline). subjects will receive iron supplement dosages of 60 mg with stable iron isotopes 54fe, 57fe, 58fe in form of 4 mg of feso4. prior administration blood samples will be collected to monitor shep and iron status markers. outcome: the combined use of stable iron isotopes and a sensitive shep assay will allow for better understanding of the iron-hepcidin relationship and this may enable design of more effective ois regimens.


Eligibility criteria:
inclusion criteria: * generally healthy, no blood donation in the last 4 months, not pregnant, not lactating, not taking vitamin and mineral supplements 2 weeks prior the study, non smoker, weight \<65 kg, bmi between 18 and 25. * no anemia (defined as 11.7 g/dl, serum ferritin level \< 20 microgram/l).

Keywords: hepcidin iron bioavailability iron supplementation
4 week combination of bi 207127 na with peg-ifn and ribavirin in chronic hcv patients

Conditions: Hepatitis C, Chronic

Summary: the main purpose of this clinical trial with bi 207127 is to see the effect of 4 week combination of bi 207127 with peginterferon alfa (peg-ifn) and ribavirin (rbv) on hepatitis c virus (hcv) virus load and how safe bi 207127 is in this combination in hcv infected patients.


Eligibility criteria:
inclusion criteria: 1. hcv genotype 1 2. hcv viral load \>100,000 iu/ml 3. histology or fibroscan to rule out cirrhosis 4. absence of retinopathy 5. treatment naive patients and treatment experienced patients 6. age 18 - 70 years 7. male or female with documented hysterectomy or postmenopausal exclusion criteria: 1. fertile males not willing to use an adequate form of contraception 2. pretreatment with any hcv-polymerase inhibitor 3. any concurrent disease if clinically significant based on the investigator's medical assessment 4. current alcohol or drug abuse, or history of the same 5. positive test for hiv or hbs 6. history of malignancy 7. planned or concurrent usage of any other pharmacological therapy including any antiviral therapy or vaccination 8. usage of any investigational drug within thirty (30) days prior to enrolment or 5 halflives, whichever is longer 9. any clinically significant laboratory abnormalities based on the investigator's medical assessment at screening 10. patients treated with any interferon (approved or investigational) or peg-ifn and/or ribavirin within 3 months prior to screening 11. known hypersensitivity to drugs or excipients; further exclusion criteria apply
sbrt plus lenvatinib and tace for advanced primary hcc: a phase 3 trial (search)

Conditions: Advanced Hepatocellular Carcinoma

Summary: this is a phase 3, multicentri, randomised, open label study. the purpose is to investigate the safety and efficacy of stereotactic body radiation therapy (sbrt) combined with transarterial chemoembolization (tace) and lenvatinib (len) in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus.


Eligibility criteria:
inclusion criteria: 1. age 18-75 years old; 2. patients with primary advanced hcc (in accordance with aasld2018 guidelines for the diagnosis of hcc), without any previous treatment; 3. there is at least one measurable lesion in the liver according to mrecist criteria, single tumor ≤ 10.0 cm or multiple tumors and tumor burden ≤50% , with portal vein tumor embolus; 4. ecog score 0-1; 5. child-pugh class a; 6. expected survival time ≥ 3 months; 7. blood, liver and kidney function meet the following conditions: neutrophil count ≥ 1.5 × 10 9 /l; platelet count ≥ 60 × 10 9 /l; hemoglobin ≥ 90 g/l; serum albumin ≥ 30 g/l; bilirubin ≤ 50 umol/l; ast, alt ≤ 5 times the upper limit of normal, alp ≤ 4 times the upper limit of normal; prolongation of prothrombin time not to exceed the upper limit of normal by 6 seconds; creatinine ≤ 1.5 times the upper limit of normal. exclusion criteria: 1. extrahepatic metastases; 2. previous history of liver or adjacent tissue radiation; 3. previous history of hepatic encephalopathy, refractory ascites or gastric esophageal varices; 4. there are contraindications to tace treatment, such as portosystemic shunt, liver flow ablation, significant atherosclerosis; 5. hypersensitivity to intravenous contrast agents; 6. pregnant or lactating women or subjects with family planning within two years; 7. with hiv, syphilis infection; 8. accompanied by other malignant tumors or suffering from other malignancies within 5 years before enrollment; 9. allogeneic organ transplant recipients; 10. severe dysfunction of heart and kidney or other organs; 11. active severe infection \> grade 2 (nci-ctc version 5); 12. suffering from mental and psychological diseases may affect informed consent; 13. unable to take oral medication; 14. participated in other drug clinical trials within 12 months before enrollment; 15. active gastric or duodenal ulcers within 3 months before enrollment.

Keywords: sbrt tace lenvatinib
compare the efficacy of acupuncture therapy and carbamazepine oral dosage in patients with carpal tunnel syndrome by multiple excitability test

Conditions: Carpal Tunnel Syndrome; Multiple Excitability Test

Summary: the goal of the study is to utilize bctq(boston carpal tunnel questionnaire), vas (visual analog scale), ncs (nerve conduction study), and met(multiple excitability test) to evaluate and compare the efficacy of acupuncture therapy and carbamazepine in patients with carpal tunnel syndrome.


Eligibility criteria:
inclusion criteria: * age greater than 20 years old * outpatient or inpatient subject with numbness of arm, clinically met diagnostic criteria of aaem(american association of electrodiagnostic medicine cts task force), and proven to have distal motor neurological disorder through nerve conduction study (distal motor latency \>4.6 msec, decreased snap \ 2.5msec)。 * willing to sign the informed consent form exclusion criteria: * subject with external hand injury or disformation * subject with polyneuritis or cervical nerve root lesions * subject with peripheral hypertrophy, hypothyroidism, multiple myeloma, or amyloidosis * allergic to carbamazepine or similar type of medicine * inability to act independently, or in the opinion of the investigator, not suitable for the study * in the opinion of the investigator, the subject requires surgical repair of the carpal tunnel syndrome, or the symptoms will be worsen result in irreversible damage to the subject if not treated with surgical repair within 3 months.

Keywords: carpal tunnel syndrome multiple excitability test nerve conduction study qtracw carbamazepine acupuncture
pre-operative withdrawal of aspirin in laparoscopic inguinal hernia repair

Conditions: Inguinal Hernia

Summary: this study aims to assess the need to stop aspirin before elective laparoscopic inguinal hernia repair. it will consist of 2 arms: patients who continue to take aspirin perioperatively and patients who stop aspirin 5-7 days before the surgery.

this study aims to assess the need to stop aspirin before elective laparoscopic inguinal hernia repair. it will consist of 2 arms: patients who continue to take aspirin perioperatively and patients who stop aspirin 5-7 days before the surgery. simple randomization will be performed and allocation is via closed envelope method. the surgeon will be blinded regarding the usage of aspirin. the primary outcome is the incidence of post-operative hematoma formation within the first 24 hours after surgery. the secondary outcomes are the incidence of post-operative seroma formation within 24 hours, the incidence of post-operative hematoma requiring intervention (including blood transfusion, percutaneous drainage and surgical hemostasis) within 30 days, pain at regular intervals and the incidence of other post-operative complications.

Eligibility criteria:
inclusion criteria: * patients with a diagnosis of inguinal hernia undergoing laparoscopic repair * age 21-80 years * patients taking aspirin * bmi 18-30 exclusion criteria: * age \ 80years * recurrent inguinal hernia * coagulopathy * patients who can't stop aspirin * bmi \ 30

Keywords: inguinal hernia laparoscopic inguinal hernia repair aspirin
added value of contrast-enhanced ultrasound for bi rads 4a nodules

Conditions: Ultrasound; Breast Cancer; Pathology

Summary: the aim of this study was to investigate the added value of contrast-enhanced ultrasound (ceus) for differentiating low risk patients with breast nodules categorized as 4a using the breast imaging reporting and data system (bi-rads).

the aim of this study was to investigate the added value of contrast-enhanced ultrasound (ceus) for differentiating low risk patients with breast nodules categorized as 4a using the breast imaging reporting and data system (bi-rads). the study included patients with 4a nodules confirmed by core biopsy and/or surgery. the ceus parameters were assessed to evaluated the added value in bi-rads 4a nodules

Eligibility criteria:
inclusion criteria: patients with nodules which were sonographically classified as bi-rads 4 a breast lesion exclusion criteria: (i) absence of a pathologic diagnosis; (ii) presence of breast nodules that were too large to compare with normal parenchyma; (iii) patients with radiotherapy and chemotherapy of breast cancer; and (iv) skin disorders.
a study of oxybutynin for the treatment of urge urinary incontinence

Conditions: Urinary Incontinence, Urge

Summary: the purpose of this study is to determine the safety of three doses of oxybutynin for the treatment of urge urinary incontinence.


Eligibility criteria:
inclusion criteria: * females 18 to 75 years of age * has reported symptoms of urge urinary incontinence/overactive bladder exclusion criteria: * is pregnant or lactating * has had lower urinary tract surgery within 6 months prior to screening * has a history of urinary retention

Keywords: urinary incontinence, urge urinary urge incontinence urge incontinence over active bladder
influence of diet on pregnancy with polyhydramnios

Conditions: Polyhydramnios

Summary: to evaluate the effect of a diet that is suited for gestational diabetes mellitus on amniotic fluid index in women with idiopathic polyhydramnios.


Eligibility criteria:
inclusion criteria: * pregnant women between 24-37 pregnancy weeks, singleton pregnancy, diagnosed with afi at 95% or more by gestational age * express their consent to participate in the study and try to make the recommended dietary change for at least two consecutive weeks from the moment the guidelines are given. * without a medical indication for an immediate delivery exclusion criteria: * medical recommendation for delivery within two weeks of diagnosis * condition of non-idiopathic amniotic fluid: gestational or pre-gestational diabetes, fetal malformation, proof of fetal infection * premature rupture or membranes * twins pregnancy
evaluation of cccdna and total hbv dna kinetics in lymphocytes, total blood and serum in chronic hepatitis b patients treated with adefovir dipivoxil and peg interferon alpha 2a

Conditions: Chronic Hepatitis B

Summary: serum hbv dna is a referent but insufficient marker of therapeutic follow-up in chronic hepatitis b treatment. intra hepatic cccdna disappearance reflects hbv eradication in the liver. intra lymphocyte cccdna could be a new marker of hbv eradication after treatment. the major interest of this marker is that it can be measured by a simple blood test instead of a liver biopsy.

- studying intra lymphocyte and blood cccdna: before inclusions, d0 then each month during the first three months each three months during treatment and follow-up. - viral kinetics:before inclusions, at d0, then monthly till the end of treatment and follow-up: evolution of quantitative viraemia in serum evolution of quantitative viraemia in circulating lymphocytes evolution of quantitative viraemia in total blood - studying viral genotypes

Eligibility criteria:
inclusion criteria: * male and female patients \>18 years of age and \<70 years of age * patients aghbs+ and aghbe+ or aghbe-, and b viral dna \>104 copies/ml pcr cobas monitor * patients treated with adefovir dipivoxil and peg interferon alpha 2a * chronic liver disease consistent with chronic hepatitis b infection on a biopsy obtained within the past 24 months * naïve patients or patients having a relapse or a therapeutic failure after monotherapy lamivudine or interferon, or bitherapy interferon alpha-lamivudine exclusion criteria: * co-infection hiv, hcv

Keywords: chronic hepatitis b ccc dna kinetics total hbv dna kinetics adefovir-dipovixil peg interferon alpha 2a